News and Press Releases July 29, 2010   JT's Consolidated Financial Results Continued growth in International Tobacco Business(PDF file) April 28, 2010   JT's Consolidated Financial Results Exceeds the Original Forecast Announced in 'JT-11' Full Fiscal Year Ended March 31, 2010(PDF file) February 9, 2010   JT Increases Annual EBITDA Forecast by JPY 9 billion and Annual Net Income Forecast by JPY 14 billion(PDF file) October 29, 2009   JT Upwardly Revises Forecasted Annual EBITDA by JPY 30 billion and Net Income by JPY 8 billion(PDF file) July 30, 2009   JT has Embarked on a Solid Start to Achieving its Fiscal Year Outlook Ending March 31, 2010(PDF file) April 30, 2009   JT Posts Record Net Sales and EBITDA for the Fiscal Year that Ended March 2009(PDF file) March 23, 2009   Launch of REMITCH(R) CAPSULES 2.5 μg , new oral antipruritus drug February 9, 2009   JT Forecasts Record Net Sales and EBITDA for Full Fiscal Year Ending March 2009 Following Robust Nine-Month Consolidated Financial Results(PDF file) January 21, 2009   Manufacturing and marketing approval for REMITCH(R) CAPSULES 2.5 μg , oral antipruritus drug, in Japan October 30, 2008   JT Upwardly Revises Results Forecast and Announces Consolidated Financial Results for 6-Month Period that Ended September 30, 2008(PDF file) September 25, 2008   Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis(PDF file) July 31, 2008   JT Reports Consolidated Financial Results for the First Quarter that Ended June 30, 2008 May 1, 2008   JT Reports Consolidated Financial Results For the Full Fiscal Year that Ended March 31, 2008 February 7, 2008   JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 October 31, 2007   JT Reports Consolidated Financial Results for the First Fiscal Half that Ended September 30, 2007 September 26, 2007   JT and Torii Sign Licensing Agreement with Keryx for Development and Commercialization of Hyperphosphatemia Drug in Japan August 9, 2007   JT Announces its First-Quarter Consolidated Financial Results and Gallaher Integration Plan(PDF file) April 27, 2007   JT Reports Consolidated Financial Results for the Full Fiscal Year that Ended March 31, 2007(PDF file) February 8, 2007   JT Reports Consolidated Financial Results for the Nine-Month Period that Ended December 31, 2006 (PDF file) December 28, 2006   JT Announces Licensing Agreement for New Antibody Drug Candidate with MedImmune November 28, 2006   New Drug Application of Antipruritic Agent "TRK-820" for the Treatment of Severe Pruritus in Hemodialysis Patients in Japan October 31, 2006   JT Reports Consolidated Interim Financial Results For the First Fiscal Half that Ended September 30, 2006(PDF file) July 31, 2006   JT Reports Consolidated Financial Results for the First Quarter that Ended June 30, 2006(PDF file) April 28, 2006   JT Reports Consolidated Financial Results for the Full Fiscal Year that Ended March 31, 2006(PDF file) April 18, 2006   JT Concludes Licensing Agreement for a New Drug Candidate with GlaxoSmithKline February 17, 2006   JT Reports Consolidated Financial Results for the Nine Month Period That Ended December 31, 2005(PDF file) October 31, 2005   JT Reports Consolidated Interim Financial Results For the First Fiscal Half That Ended September 30, 2005(PDF file) August 1, 2005   JT Reports Consolidated Financial Results for the First Quarter that Ended June 30, 2005 (PDF file) April 27, 2005   JT Reports Consolidated Financial Results for the Fiscal Year that Ended March 31, 2005 (PDF file) April 8, 2005   JT and Torii Pharmaceutical to Launch New HIV Treatment Drugs in Japan March 22, 2005   JT Concludes License Agreement on JT's Anti-HIV drug with Gilead March 16, 2005   Toray, JT, Torii Pharmaceutical Agree Co-development and Marketing February 17, 2005   JT's consolidated Financial Results for the Nine-Month Period that Ended December 31, 2004 (PDF file) ©2007 Akros Pharma Inc. All rights reserved.